EARNEST Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

EARNEST Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-99	Closed	-$18K	–	1199
2021 Q2	$18K	Hold	99	–	–	﹤0.01%	517
2021 Q1	$15K	Hold	99	–	–	﹤0.01%	540
2020 Q4	$15K	Hold	99	–	–	﹤0.01%	525
2020 Q3	$11K	Hold	99	–	–	﹤0.01%	549
2020 Q2	$11K	Hold	99	–	–	﹤0.01%	550
2020 Q1	$9K	Hold	99	–	–	﹤0.01%	551
2019 Q4	$11K	Hold	99	–	–	﹤0.01%	584
2019 Q3	$10K	Hold	99	–	–	﹤0.01%	595
2019 Q2	$13K	Hold	99	–	–	﹤0.01%	532
2019 Q1	$13K	Hold	99	–	–	﹤0.01%	521
2018 Q4	$10K	Hold	99	–	–	﹤0.01%	554
2018 Q3	$14K	Hold	99	–	–	﹤0.01%	507
2018 Q2	$12K	Hold	99	–	–	﹤0.01%	536
2018 Q1	$11K	Hold	99	–	–	﹤0.01%	549
2017 Q4	$12K	Buy	+99	New	+$12.1K	﹤0.01%	521
2017 Q1	–	Sell	-99	Closed	-$12K	–	1020
2016 Q4	$12K	Buy	+99	New	+$12.1K	﹤0.01%	492

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

EARNEST Partners's ALXN Position: Q3 2021 in Review

EARNEST Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 99 shares — an estimated $18K sold.

EARNEST Partners first reported a position in ALXN in Q4 2016 and held it in 16 quarters. The position peaked at $18K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

EARNEST Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
EARNEST Partners sold 99 Alexion Pharmaceuticals shares in Q3 2021, an estimated $18K.
EARNEST Partners first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 16 quarters.
EARNEST Partners's Alexion Pharmaceuticals position peaked at $18K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on EARNEST Partners's 13F filing for Q3 2021, filed 15 Nov 2021.